This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
60+ FDA-approved peptide drugs with 150+ in clinical trials. Antiviral peptides offer high specificity but face stability and delivery challenges addressable by chemical modification.
Why it matters
New antiviral drugs are always needed. Peptides offer a different approach from traditional small molecules with potentially better specificity.
The numbers in context
60+ FDA approved; 150+ in clinical trials; since 1920; challenges: serum stability, oral BA, permeability; addressable by chemical modification
How the study worked
Book chapter reviewing antiviral peptide drugs, their mechanisms, advantages, disadvantages, and comparison with small molecules.
Who was studied
N/A (review of antiviral peptide drug landscape)
What this study cannot tell us
Review/book chapter. Broad overview rather than deep analysis of specific antiviral peptides. Field is rapidly evolving.
Read the original research
Peptide-Based Antiviral Drugs.
Advances in experimental medicine and biology, 1322, 261-284
Citation
Murugan, N Arul; Raja, K Muruga Poopathi; Saraswathi, N T. (2021). Peptide-Based Antiviral Drugs.. Advances in experimental medicine and biology, 1322, 261-284. https://doi.org/10.1007/978-981-16-0267-2_10